Clinical Trials in Florida

View paid research studies that are recruiting in Florida. Filter by distance, duration, and inclusion criteria to find clinical trials that pay well for your time.

Condition

Location

Distance

Age

Clinical Trials Clinical Trials in Florida

Phase-Based Progress Estimates

READY4Life Programming - Classroom Instructionfor Problem Solving

The U.S. Committee for Refugees and Immigrants (USCRI) has developed the Relationships, Education, Advancement, and Development for Youth for Life (READY4Life) Program. This is a 16-hour program for immigrants/refugees, ages 14 to 24. The program is designed to help young immigrants and refugees prepare for a successful life in the United States. The program is taught by USCRI program staff and is being implemented at eight sites across the U.S.: Cleveland, Ohio; Colchester, Vermont; Des Moines, Iowa; Miami, Florida; Philadelphia, Pennsylvania; Raleigh, North Carolina; Saint Paul, Minnesota; and Twin Falls, Idaho. The project also includes a rigorous evaluation component, featuring a Randomized Control Trial (RCT) design.

Phase-Based Progress Estimates

CTP-543for Hepatic Impairment

This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.

Phase-Based Progress Estimates

Test - Bimatoprost 0.01% Ophthalmic Solutionfor Glaucoma, Open-Angle

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.

Phase-Based Progress Estimates

RO7200220for Diabetic Macular Edema (DME)

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 52 weeks.

Phase-Based Progress Estimates

Ubrogepantfor Migraine

This study is evaluating whether a drug can be used to treat migraine in children and adolescents.

Phase-Based Progress Estimates

Dupilumabfor Asthma

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.

Phase-Based Progress Estimates

BIO89-100for Nonalcoholic Steatohepatitis

This study is evaluating whether a drug called BIO89-100 can help treat people with nonalcoholic fatty liver disease.

Phase-Based Progress Estimates

VIR-7831for COVID-19

Pembroke Pines, FL

Waitlist Available

Pembroke Pines, FL

This study is evaluating whether a drug called sotrovimab can help treat people with mild/moderate COVID-19.

Phase-Based Progress Estimates

Alpha-1 15%for Alpha1-Antitrypsin Deficiency

This study is evaluating whether a single dose of Alpha-1 15% can be safely administered to people with Alpha-1 Antitrypsin Deficiency.

Phase-Based Progress Estimates

Quality-of-Life Assessmentfor Metastatic Lung Adenocarcinoma

Locally Advanced

This study is evaluating whether a combination of chemotherapy and immunotherapy may help treat patients with advanced non-small cell lung cancer.

Phase-Based Progress Estimates

THR-149 Selected Dose Levelfor Diabetes Mellitus

This study is evaluating whether a drug may help treat wet age-related macular degeneration.

Phase-Based Progress Estimates

Risankizumabfor Ileocolitis

Oklahoma City, OK

Oklahoma City, OK

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease (CD). Ustekinumab is an approved drug for the treatment of moderate and severe CD. Participants are randomly assigned to one of the three treatment groups. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to ustekinumab. Around 508 adult participants with moderate to severe CD will be enrolled in approximately 307 sites worldwide. In Part 1, participants assigned to risankizumab will receive intravenous (IV) doses of risankizumab at Week 0, 4,8 and subcutaneous (SC) doses every 8 weeks thereafter through Week 48. Participants assigned to ustekinumab will receive intravenous (IV) dose of ustekinumab at Week 0 and subcutaneous (SC) doses every 8 weeks thereafter through Week 48. In Part 2, participants who received risankizumab in Part 1 and completed the Week 48 visit will continue to receive SC risankizumab for up to an additional 220 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Phase-Based Progress Estimates

Donanemabfor Alzheimer Disease

Waitlist Available

This study is evaluating whether a drug may help treat early Alzheimer's disease.

Phase-Based Progress Estimates

PR006for Semantic Dementia

This study is evaluating whether a drug may help treat frontotemporal dementia.

Phase-Based Progress Estimates

Dihydroergotaminefor Migraine

Waitlist Available

This study is evaluating whether a nasal spray may help reduce the pain of migraines.

Phase-Based Progress Estimates

Intensity-Modulated Radiation Therapyfor Anal Cancer

Colorado Springs, CO

Colorado Springs, CO

This study is evaluating whether a lower dose of chemotherapy and radiation may be as effective as a higher dose for treating anal cancer.

Phase-Based Progress Estimates

Mepolizumabfor Airflow Obstruction, Chronic

Boynton Beach, FL

Boynton Beach, FL

This study is evaluating whether a drug which blocks certain immune cells may help reduce the number of exacerbations in individuals with chronic obstructive pulmonary disease.

Phase-Based Progress Estimates

SEP-363856 100mgfor Schizophrenia

This study is evaluating whether an investigational drug may help treat schizophrenia.

Phase-Based Progress Estimates

Venetoclaxfor Multiple Myeloma

Waitlist Available

1 Prior Treatment

This study is evaluating whether a combination of two drugs may help treat multiple myeloma.

Phase-Based Progress Estimates

Tofacitinibfor Juvenile Idiopathic Arthritis (JIA)

Saint Pertersburg, FL

Saint Pertersburg, FL

This study is evaluating whether a drug called tofacitinib may be safe and effective for treating juvenile idiopathic arthritis.

Phase-Based Progress Estimates

PCV15for Pneumococcal Infections

Fort Pierce, FL

Fort Pierce, FL

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

Phase-Based Progress Estimates

Ocrelizumabfor Multiple Sclerosis

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.

Phase-Based Progress Estimates

Tralokinumabfor Eczema, Infantile

The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection with Device A in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).

Phase-Based Progress Estimates

Luvadaxistatfor Schizophrenia

Pico Rivera, CA

Pico Rivera, CA

Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in subjects with schizophrenia.

Phase-Based Progress Estimates

VRDN-001for Thyroid Diseases

Minneapolis, MN

Minneapolis, MN

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service